Based on the data of the phase 1 study showing differential response to CAIX/XII specific inhibitor SLC-0111 among patients with colorectal cancer [48], we questioned whether there is a characteristic differential expression pattern of both CAs in colorectal tumors, which could explain the differential response. Here, CA9 is linked to colorectal neoplasm.